# 💀 IO PAN-CANCER VALIDATION: DATA VERIFICATION STATUS

**Date:** January 25, 2026  
**Status:** ⚠️ **BLOCKED - NEED SUPPLEMENTARY DATA EXTRACTION**

---

## 📊 VERIFIED DATASETS SUMMARY

### Ovarian Cancer IO Datasets:

| Dataset | n | Treatment | RNA-seq | Key Genes | Response in GEO | Status |
|---------|---|-----------|---------|-----------|-----------------|--------|
| **GSE206422** | 73 samples, ~40 pts | Pembro+Bev+Cyclo | ✅ 58K genes | ✅ 20/21 (96%) | ❌ Missing | ⚠️ Need supp data |
| **GSE271757** | 97 samples | Pembro+Chemo | ✅ Available | ⏳ Not checked | ❌ Missing | ⚠️ Need supp data |
| GSE227666 | ? | NACT±Pembro | ⏳ | ⏳ | ⏳ | ⏳ Not checked |

### Published Response Data (From Papers):

| Dataset | Publication | ORR | Responders | Non-Responders | Data Location |
|---------|-------------|-----|------------|----------------|---------------|
| **GSE206422** | Nat Commun Dec 2024 (PMID 39638782) | 47.5% | 19 (CR+PR) | 21 (SD+PD) | **Supplementary** |
| GSE271757 | Unknown | Unknown | Unknown | Unknown | Unknown |

---

## 🚫 BLOCKING ISSUE

### Problem:
**Response labels are NOT in GEO metadata for any ovarian IO dataset.**

They are in publication supplementary files (PDF/Excel), not programmatically accessible.

### Impact:
- Cannot compute AUC without patient-level response labels
- Cannot validate model on ovarian cancer
- Publication blocked until resolved

---

## 📋 AGENT X TASK SPECIFICATION

### Task 1: Extract GSE206422 Response Data

**Publication:** Nature Communications, December 5, 2024  
**PMID:** 39638782  
**DOI:** 10.1038/s41467-024-54598-1  
**Title:** *Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer*

**Target Data:**
1. Supplementary Table with patient-level clinical data
2. Must contain: Patient ID (matching format "1-BLBX", "2-BLBX", etc.) + Response (CR/PR/SD/PD)
3. Or: Figure 1 waterfall plot with patient identifiers

**Output Format Required:**
```csv
patient_id,response,pfs_months
1,PR,18.5
2,SD,6.2
3,CR,24.0
...
```

**Key Mapping:**
- Sample names in GEO: "1-BLBX", "2-BLBX", etc.
- Patient ID = number before hyphen (1, 2, 3, ...)
- BLBX = baseline (pre-treatment) - USE THESE
- Response needed for each patient

---

### Task 2 (Backup): Find Alternative Dataset

If GSE206422 supplementary not accessible, search for:

1. **TOPACIO Trial** (NCT02657889) - Niraparib + Pembrolizumab in ovarian
   - Published with response data?
   - GEO deposition?

2. **KEYNOTE-028** (NCT02054806) - Pembrolizumab in ovarian
   - May have GEO data

3. **Other IO ovarian trials** with public RNA-seq + response

---

## ✅ WHAT'S READY FOR ANALYSIS (Once response data obtained)

### GSE206422 Analysis Pipeline:

```python
# Step 1: Load expression data
counts = pd.read_csv('/tmp/geo_cache/GSE206422_RawCounts.csv')

# Step 2: Filter to baseline samples (BLBX)
baseline_cols = [c for c in counts.columns if 'BLBX' in c]

# Step 3: Normalize (TPM or log2CPM)
# Step 4: Compute TIL score (13 genes)
# Step 5: Compute Exhaustion score (7 genes)
# Step 6: Apply melanoma model coefficients
# Step 7: Compute AUC vs response

# Expected output: AUC with 95% CI
```

### Baseline Sample Count:

| Sample Type | Count | Use Case |
|-------------|-------|----------|
| **BLBX** (baseline) | ~40 | ✅ Primary analysis |
| C4BX (on-treatment) | ~25 | Secondary (response dynamics) |
| EOTBX (end of treatment) | ~5 | Secondary |

---

## 📋 DECISION POINTS

### If Agent X Succeeds:

1. Obtain response mapping
2. Compute TIL + Exhaustion scores for BLBX samples
3. Apply melanoma model
4. Report AUC
5. **If AUC > 0.60:** Proceed with multi-cancer paper
6. **If AUC ~ 0.50:** Model doesn't transfer to ovarian

### If Agent X Fails:

1. Try contacting authors directly
2. Use alternative endpoint (durable response from figure)
3. Pivot to NSCLC or other cancer type
4. Document ovarian as "not validated" in paper

---

## 💀 HONEST STATUS

| Component | Status | Confidence |
|-----------|--------|------------|
| **Ovarian IO data exists** | ✅ Confirmed | 100% |
| **RNA-seq quality sufficient** | ✅ Confirmed | 100% |
| **Key genes present** | ✅ Confirmed | 96% coverage |
| **Response data accessible** | ❌ **NOT CONFIRMED** | 0% |
| **Validation feasible** | ⚠️ **BLOCKED** | Depends on Agent X |

---

## 📋 NEXT ACTIONS

| Priority | Action | Owner | Deadline |
|----------|--------|-------|----------|
| **P0** | Extract GSE206422 response from Nat Commun supplementary | Agent X | ASAP |
| **P1** | Verify GSE227666 and other datasets | Zo | If P0 fails |
| **P2** | Check NSCLC datasets (GSE179994) | Zo | Parallel |
| **P3** | Alternative endpoint analysis | Zo | If all fail |

---

**Awaiting Agent X data extraction before proceeding with analysis.**
